[-2]proPSA versus ultrasensitive PSA fluctuations over time in the first year from radical prostatectomy, in an high-risk prostate cancer population: A first report

about

[-2]proPSA versus ultrasensitive PSA fluctuations over time in the first year from radical prostatectomy, in an high-risk prostate cancer population: A first report

Item

http://www.wikidata.org/entity/Q35969948

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

2016年论文

@zh

2016年论文

@zh-cn

name

[-2]proPSA versus ultrasensiti ...... cer population: A first report

@ast

[-2]proPSA versus ultrasensiti ...... cer population: A first report

@en

type

Item

label

[-2]proPSA versus ultrasensiti ...... cer population: A first report

@ast

[-2]proPSA versus ultrasensiti ...... cer population: A first report

@en

prefLabel

[-2]proPSA versus ultrasensiti ...... cer population: A first report

@ast

[-2]proPSA versus ultrasensiti ...... cer population: A first report

@en

P1476

[-2]proPSA versus ultrasensiti ...... cer population: A first report

@en

P2093

A Sottile

http://www.w3.org/2001/XMLSchema#string

C Fiori

http://www.w3.org/2001/XMLSchema#string

F Porpiglia

http://www.w3.org/2001/XMLSchema#string

S De Luca

http://www.w3.org/2001/XMLSchema#string

P2860

Natural history of progression after PSA elevation following radical prostatectomy.

Prostate specific antigen: a decade of discovery--what we have learned and where we are going.

Predicting 15-year prostate cancer specific mortality after radical prostatectomy.

A prospective, multicenter, National Cancer Institute Early Detection Research Network study of [-2]proPSA: improving prostate cancer detection and correlating with cancer aggressiveness

Prostate specific antigen only progression of prostate cancer.

A multicenter study of [-2]pro-prostate specific antigen combined with prostate specific antigen and free prostate specific antigen for prostate cancer detection in the 2.0 to 10.0 ng/ml prostate specific antigen range.

Salvage radiotherapy for recurrent prostate cancer after radical prostatectomy.

Ultrasensitive prostate specific antigen after prostatectomy reliably identifies patients requiring postoperative radiotherapy

A pilot study evaluating serum pro-prostate-specific antigen in patients with rising PSA following radical prostatectomy.

The 2005 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma.

P304

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1186/S12894-016-0131-0

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Roberto Mario Scarpa

Roberto Passera

P577

2016-03-24T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27013515

http://www.w3.org/2001/XMLSchema#string

P932

4806444

http://www.w3.org/2001/XMLSchema#string